PMID- 34060970
OWN - NLM
STAT- MEDLINE
DCOM- 20211101
LR  - 20211101
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 62
IP  - 10
DP  - 2021 Oct
TI  - Mitochondrial metabolism: powering new directions in acute myeloid leukemia.
PG  - 2331-2341
LID - 10.1080/10428194.2021.1910685 [doi]
AB  - There has been an explosion of knowledge about the role of metabolism and the 
      mitochondria in acute myeloid leukemia (AML). We have also recently seen several 
      waves of novel therapies change the treatment landscape for AML, such as the 
      selective B-cell lymphoma 2 (BCL-2) inhibitor venetoclax. In this new context, we 
      review the rapidly advancing literature on the role of metabolism and the 
      mitochondria in AML pathogenesis, and how these are interwoven with the 
      mechanisms of action for novel therapeutics in AML. We also review the role of 
      oxidative phosphorylation (OxPhos) in maintaining leukemia stem cells (LSCs), how 
      recurrent genomic alterations in AML alter downstream metabolism, and focus on 
      how the BCL-2 pathway and the mitochondria are inextricably linked in AML. Thus, 
      we provide an overview of the mitochondria and metabolism in the context of our 
      new therapeutic world for AML and outline how targeting these vulnerabilities may 
      produce novel therapeutic strategies.
FAU - Stubbins, Ryan J
AU  - Stubbins RJ
AUID- ORCID: 0000-0002-4718-5212
AD  - Division of Hematology, Department of Medicine, University of British Columbia, 
      Vancouver, Canada.
FAU - Maksakova, Irina A
AU  - Maksakova IA
AD  - Terry Fox Laboratory, BC Cancer Research Centre, University of British Columbia, 
      Vancouver, Canada.
FAU - Sanford, David S
AU  - Sanford DS
AD  - Division of Hematology, Department of Medicine, University of British Columbia, 
      Vancouver, Canada.
FAU - Rouhi, Arefeh
AU  - Rouhi A
AD  - Terry Fox Laboratory, BC Cancer Research Centre, University of British Columbia, 
      Vancouver, Canada.
FAU - Kuchenbauer, Florian
AU  - Kuchenbauer F
AD  - Division of Hematology, Department of Medicine, University of British Columbia, 
      Vancouver, Canada.
AD  - Terry Fox Laboratory, BC Cancer Research Centre, University of British Columbia, 
      Vancouver, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20210601
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - *Antineoplastic Agents/therapeutic use
MH  - Humans
MH  - *Leukemia, Myeloid, Acute/drug therapy/genetics/metabolism
MH  - Mitochondria/metabolism
MH  - Oxidative Phosphorylation
OTO - NOTNLM
OT  - Acute myeloid leukemia
OT  - BCL-2
OT  - OxPhos
OT  - mitochondria
OT  - venetoclax therapy resistance
EDAT- 2021/06/02 06:00
MHDA- 2021/11/03 06:00
CRDT- 2021/06/01 12:16
PHST- 2021/06/02 06:00 [pubmed]
PHST- 2021/11/03 06:00 [medline]
PHST- 2021/06/01 12:16 [entrez]
AID - 10.1080/10428194.2021.1910685 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2021 Oct;62(10):2331-2341. doi: 10.1080/10428194.2021.1910685. 
      Epub 2021 Jun 1.